CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,123,947 | +25.6% | 372,146 | +82.9% | 0.01% | +42.9% |
| Q2 2023 | $6,467,644 | +46.3% | 203,449 | +12.3% | 0.01% | +40.0% |
| Q1 2023 | $4,420,029 | -24.5% | 181,223 | -2.3% | 0.01% | -28.6% |
| Q4 2022 | $5,852,058 | +13.2% | 185,544 | 0.0% | 0.01% | +16.7% |
| Q3 2022 | $5,171,000 | +6.9% | 185,544 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $4,839,000 | -29.4% | 183,008 | -6.5% | 0.01% | 0.0% |
| Q1 2022 | $6,855,000 | -2.2% | 195,808 | -9.4% | 0.01% | 0.0% |
| Q4 2021 | $7,006,000 | +36.1% | 216,108 | +23.9% | 0.01% | +20.0% |
| Q3 2021 | $5,147,000 | +35.1% | 174,476 | +12.9% | 0.01% | +25.0% |
| Q2 2021 | $3,809,000 | +141.8% | 154,590 | +34.8% | 0.00% | +100.0% |
| Q1 2021 | $1,575,000 | +155.7% | 114,715 | +208.7% | 0.00% | +100.0% |
| Q4 2020 | $616,000 | – | 37,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |